Alignment Healthcare (ALHC) saw its largest California contract downgraded to 3.5 stars by CMS for the 2027 Medicare Advantage Part D Release, rendering it ineligible for bonus payments and pressuring revenue prospects. The pre-market drop of about 24% to $6.60 signals serious investor concern and potential continued volatility as regulatory risk compounds. Additional pre-market moves were seen in ENTX, T, VZ and other names, underscoring a broader risk-off tone.
Alignment Health reported six of seven MA contracts earned 4+ stars in CMS's 2027 STAR ratings, with three plans at 4.5 stars. The California H3815 HMO received 3.5 stars, which Alignment says misrepresents long-standing quality. The company plans administrative remedies and litigation while pursuing its growth plan and aiming to restore the H3815 rating to 4+ stars.
Alignment Healthcare posted Q2 net income of $36.56 million, up from $15.65 million a year earlier, with revenue of $1.3 billion, +31% year over year. Medicare Advantage membership rose to 294,100, a 31% YoY gain, helping premium revenue and driving a lower medical benefit ratio near 86%. The results beat expectations and underscore AI-enabled care platforms as a growth driver.
Alignment Healthcare enhances its leadership structure with John Kao as chairman, aiming to drive long-term growth in its Medicare Advantage business. The company announced an improved medical benefit ratio and will join the S&P SmallCap 600, indicating increased market confidence and potential for future expansion.
Alignment Healthcare reported a strong first quarter with $1.24 billion in revenue, marking 33.3% year-over-year growth. The surge in Medicare Advantage membership and improved profitability metrics are key indicators of sustained momentum. Guidance has been raised across various operational metrics, signaling a positive outlook that could drive share performance.
